Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: A multicentre, double-blind, randomized, placebo-controlled, parallel-group study

Cephalalgia

Volumn 26, Issue 7, 2006, Pages 790-800

  Silberstein, S D ^a,f   Gobel H ^b   Jensen, R ^c   Elkind, A H ^d   DeGryse, R ^e   Walcott, J M C M ^e   Turkel, C ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Elkind Headache Center   (United States)

^e ALLERGAN INC   (United States)

^f THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Botulinum toxin type A; Chronic tension type headache; Nociception; Sensitization

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; ASTHENIA; CHRONIC TENSION HEADACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPHAGIA; FEMALE; HEADACHE; HUMAN; INJECTION SITE BURNING; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; MUSCLE WEAKNESS; NAUSEA; NECK PAIN; PARESTHESIA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXIN TYPE A; COHORT STUDIES; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORTH AMERICA; PAIN MEASUREMENT; PLACEBO EFFECT; RISK ASSESSMENT; RISK FACTORS; TENSION-TYPE HEADACHE; TREATMENT OUTCOME;

EID: 33744493554     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2006.01114.x     Document Type: Article

References (39)

1. Schwartz BS Stewart WF Simon D Lipton RB. Epidemiology of tension-type headache. JAMA 1998 279 : 381 3.
2. Langemark M Olesen J Poulsen DL Bech P. Clinical characterization of patients with chronic tension headache. Headache 1988 28 : 590 6.
3. Schoenen J Bottin D Hardy F Gerard P. Cephalic and extracephalic pressure pain thresholds in chronic tension-type headache. Pain 1991 47 : 145 9.
4. Schoenen J Gerard P De Pasqua V Sianard-Gainko J. Multiple clinical and paraclinical analyses of chronic tension-type headache associated or unassociated with disorder of pericranial muscles. Cephalalgia 1991 11 : 135 9.
5. Jensen R. Pathophysiological mechanisms of tension-type headache: a review of epidemiological and experimental studies. Cephalalgia 1999 19 : 602 21.
6. Jensen R. Mechanisms of tension-type headache. Cephalalgia 2001 21 : 786 9.
7. Mørk H Ashina M Bendtsen L Olesen J Jensen R. Induction of prolonged tenderness in patients with tension-type headache by means of a new experimental model of myofascial pain. Eur J Neurol 2003 10 : 249 56.
8. Bendtsen L. Central sensitization in tension-type headache - possible pathophysiological mechanisms. Cephalalgia 2000 20 : 486 508.
9. Nardone R Tezzon F. The trigemino-cervical reflex in tension-type headache. Eur J Neurol 2003 10 : 307 12.
10. Ashina M. Neurobiology of chronic tension-type headache. Cephalalgia 2004 24 : 161 72.
11. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003 43 ( Suppl. 1 S16 24.
12. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003 43 ( Suppl. 1 S9 15.
13. Cui M Khanijou S Rubino J Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004 107 : 125 33.
14. Durham PL Dacy R Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004 44 : 35 43.
15. Kramer HH Angerer C Erbguth F Schmelz M Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003 250 : 188 93.
16. Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003 43 ( Suppl. 1 S25 33.
17. Smuts JA Baker MK Smuts HM Stassen JMR Rossouw E Barnard PWA. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 1999 6 ( Suppl. 4 S99 102.
18. Silberstein S Mathew N Saper J Jenkins S for the BOTOX® Migraine Clinical Research Group. Botulinum toxin type A as a migraine prophylactic treatment. Headache 2000 40 : 445 50.
19. Binder WJ Brin MF Blitzer A Schoenrock LD Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000 123 : 669 76.
20. Barrientos N Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003 4 : 146 51.
21. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003 43 : 853 60.
22. Troost BT. Botulinum toxin type A (Botox®) in the treatment of migraine and other headaches. Expert Rev Neurotherapeutics 2004 4 : 27 31.
23. Kokoska MS Glaser DA Burch CM Hollenbeak CS. Botulinum toxin injections for the treatment of frontal tension headache. J Headache Pain 2004 5 : 103 9.
24. Ondo WG Vuong KD Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004 24 : 60 5.
25. Schmitt WJ Slowey E Fravi N Weber S Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001 41 : 658 64.
26. Evers S Vollmer-Haase J Schwaag S Rahmann A Husstedt IW Frese A. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 2004 24 : 838 43.
27. Padberg M de Bruijn SF de Haan RJ Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004 24 : 675 80.
28. Mathew NT Frishberg BM Gawel M Dimitrova R Gibson J Turkel C and the BOTOX CDH Study Group. Botulinum toxin type A (Botox®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005 45 : 293 307.
29. Silberstein SD Stark SR Lucas SM Christine SN DeGryse RE Turkel CC. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clinic Proc 2005 80 : 1126 37.
30. Relja M Telarovic S. Botulinum toxin in tension-type headache. J Neurol 2004 251 : I12 4.
31. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988 8 ( Suppl. 7 S1 96.
32. Linde M May A Limmroth V Dahlof C Headache Masters Programme. Ethical aspects of placebo in migraine research. Cephalalgia 2003 23 : 491 5.
33. Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol 1998 78 : 169 83.
34. Brashear A Gordon MF Elovic E Kassicieh VD Marciniak C Do M et al. for the Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002 347 : 395 400.
35. Foster L Clapp L Erickson M Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001 56 : 1290 3.
36. Cheshire WP Abashian SW Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994 59 : 65 9.
37. Lang AM. A pilot study of botulinum toxin type A (Botox®), administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Manage 2000 10 : 108 12.
38. Freund BJ Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache 2002 42 : 1033 7.
39. Blumenfeld AM Binder W Silberstein SD Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003 43 : 884 91.